TriAltus Bioscience: Difference between revisions
Jump to navigation
Jump to search
(Created page with "'''TriAltus Bioscience''' is a company which markets a CL7/Im7 system for the production and purification of genetically engineered proteins. It was co-founded by UAB crys...") |
No edit summary |
||
| Line 5: | Line 5: | ||
* "[https://trialtusbioscience.com/blogs/protein-corner/trialtus-origin-story TriAltus{{'}} Origin Story]" (May 26, 2020) Trialtusbioscience.com | * "[https://trialtusbioscience.com/blogs/protein-corner/trialtus-origin-story TriAltus{{'}} Origin Story]" (May 26, 2020) Trialtusbioscience.com | ||
* Patchen, Tyler (October 8, 2021) "National Institutes of Health awards TriAltus Bioscience $256,000 NIH grant." {{BBJ}} | * Patchen, Tyler (October 8, 2021) "National Institutes of Health awards TriAltus Bioscience $256,000 NIH grant." {{BBJ}} | ||
* Thrailkill, Laurel (October 31, 2022) "Local bioscience company plans to double its employees, square footage." {{BBJ}} | |||
==External links== | ==External links== | ||
Latest revision as of 16:54, 31 October 2022
TriAltus Bioscience is a company which markets a CL7/Im7 system for the production and purification of genetically engineered proteins. It was co-founded by UAB crystallography researcher Dmitry Vassylyev. It is headed by CEO Bob Shufflebarger and has offices at Birmingham's Innovation Depot.
References
- Patchen, Tyler (April 17, 2020) "Birmingham company's technology to be used in COVID-19 vaccine trial." Birmingham Business Journal
- "TriAltus' Origin Story" (May 26, 2020) Trialtusbioscience.com
- Patchen, Tyler (October 8, 2021) "National Institutes of Health awards TriAltus Bioscience $256,000 NIH grant." Birmingham Business Journal
- Thrailkill, Laurel (October 31, 2022) "Local bioscience company plans to double its employees, square footage." Birmingham Business Journal
External links
- TriAltus Bioscience website